Comparison of the size of membrane microparticles of different cellular origin by dynamic light scattering

Алчинова, И. Б.; Хаспекова, С. Г.; Golubeva, N. V.; Shustova, O. N.; Антонова, О. А.; Karganov, M. Yu.; Мазуров, А. В.

doi:10.1134/s1607672916050045

Cited by 9 publications

(11 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Variations in the percentage of annexin V-positive MPs could be at least partially explained by the difference in MPs size. Earlier, using the dynamic light scattering method, for the MPs sizing, we have shown in direct comparative studies that ErMPs have an average diameter of 200-250 nm, PMPs 350-400 nm, EMPs and THP MPs 400-500 nm, and EMPs 550-600 nm [29,30,47]. We presumed that annexin V-FITC binding to small MPs was too low to provide FITC signals above the threshold noise level, which is why we measured the different percentages of annexin V-positive events in samples of MPs of different origins with different average sizes.…”

Section: Discussionmentioning

confidence: 99%

Platelet, erythrocyte, endothelial, and monocyte microparticles in coagulation activation and propagation

Lipets

Антонова

Shustova

et al. 2020

Preprint

View full text Add to dashboard Cite

1819 Background and objective: For many pathological states, microparticles are supposed to be one of the 20 causes of hypercoagulation. Although there are some indirect data about microparticles participation 21 in coagulation activation and propagation, the integral hemostasis test Thrombodynamics allows to 22 measure micropaticles participation in these two coagulation phases directly by influence on the 23 appearance of coagulation centers in plasma volume and on the rate of clot grown from surface with 24 immobilized tissue factor. 2 25 Methods: Microparticles were obtained from platelets and erythrocytes by stimulation with SFLLRN 26 and A23187, respectively, from monocytes, endothelial HUVEC culture and monocytic THP cell 27 culture by stimulation with lipopolysaccharides. Microparticles were counted by flow cytometry and 28 titrated in microparticle-depleted normal plasma in the Thrombodynamics test.29 Results: Monocyte microparticles induced the appearance of clotting centres through the TF pathway 30 at concentrations approximately 100-fold lower than platelet and erythrocyte microparticles, which 31 activated plasma by the contact pathway. For endothelial microparticles, both activation pathways 32 were essential, and their activity was intermediate. Monocyte microparticles induced plasma clotting 33 by the appearance of hundreds of clots with an extremely slow growth rate, while erythrocyte 34 microparticles induced the appearance of a few clots with a growth rate similar to that from surface 35 covered with high-density tissue factor. Patterns of clotting induced by platelet and endothelial 36 microparticles were intermediate. Platelet, erythrocyte and endothelial microparticles impacts on the 37 rate of clot growth from the surface with tissue factor did not differ significantly within the 0-38 200·10 3 /ul range of microparticles concentrations. However, at concentrations greater than 500·10 3 /ul, 39 erythrocyte microparticles increased the stationary clot growth rate to significantly higher levels than 40 do platelet microparticles or artificial phospholipid vesicles consisting of phosphatidylcholine and 41 phosphatidylserine. 42 Conclusion: Microparticles of different origins demonstrated qualitatively different characteristics 43 related to coagulation activation and propagation. 44 45 46 Introduction 47 3 48Cell destruction or activation leads to microparticles (MPs) shedding. In the blood of normal 49 donors, more than 80% of MPs are derived from platelets [1,2]. In pathological states the MPs 50 concentration and origin may change. 51There are a number of clinical works where the MPs concentration is shown to increase in 52 pathological states associated with elevated thrombotic risk. Data are represented in corresponding 53 reviews [3][4][5][6][7][8]. Many studies have also revealed elevated MPs concentration in both arterial and venous 54 thrombosis. In acute coronary syndromes, the concentration of platelet MPs (PMPs) was found to be 55 increased [9], as was the concentration of endotheli...

show abstract

Section: Discussionmentioning

confidence: 99%

Platelet, erythrocyte, endothelial, and monocyte microparticles in coagulation activation and propagation

Lipets

Антонова

Shustova

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…MPs were also collected from the culture media, cell supernatants, and plasma by centrifugation at 20,000 g for 30 min. The average diameter of all types of MVs was varying much comparing different reports [19,[23][24][25]. The plasma MPs had the smallest size similar to MPs released from platelets and THP-1 cells, while MPs from monocytes were larger, and MPs from granulocytes and ECs were the largest ones.…”

Section: Introductionmentioning

confidence: 88%

“…The plasma MPs had the smallest size similar to MPs released from platelets and THP-1 cells, while MPs from monocytes were larger, and MPs from granulocytes and ECs were the largest ones. The data obtained from various reports indicate that the size of membrane MPs depends on the type of the cells from which they originate [23]. Although MVs have been discovered for years, the understanding of the mechanism of the formation as well as the biological roles of MVs is still a matter of debate.…”

Section: Introductionmentioning

confidence: 99%

“…Recent reported findings led to advances of our understanding of the mechanism of formation and the role of MVs in many different diseases such as vascular diseases, cancer, infectious diseases, diabetes mellitus, diabetes, inflammation, and pathogen infection [24]. Inhibition of the production of MPs may serve as a novel therapeutic strategy for some diseases, especially for cancer treatment [11,23,26,27]. In the next part of this chapter, the biogenesis, properties, and biological function of MVs released from human red blood cells (RBCs) are mainly addressed.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Microvesicles Released from Human Red Blood Cells: Properties and Potential Applications

Nguyen¹,

Ly²,

Bernhardt³

2017

Novel Implications of Exosomes in Diagnosis and Treatment of Cancer and Infectious Diseases

View full text Add to dashboard Cite

Microvesicles (MVs) are small spherical fragments of plasma membrane between 50 and 1000 nm in diameter. MVs arise through direct outward budding and fission of the plasma membrane. As almost all cells, human red blood cells (RBCs) are able to release MVs into extracellular environment under stimulating or storage conditions. Recently, it has been known that MVs not only play a role in homeostasis but also have diverse functions in cell-cell interactions and in the pathogenesis of diseases. In this chapter, the formation and release of MVs from human RBCs have been described. In addition, MVs have demonstrated to be potential vehicle for transport of nucleic acid and other molecules to the target cells. Although RBC-derived MVs are potential material for the development of delivery systems, it is still a great challenge to the clinical application. Future research should pay more attention to MVs as biological targets for diagnosis and practical therapeutics of cancer and other diseases.

show abstract

“…It has been reported that diversified types of cells, including RBCs, endothelial cells, monocytes, granulocytes, and platelets, release EVs. Additionally, EVs can be isolated by various methods from cell culture media, plasma, and other biofluids [23,41,70,71]. Although several research groups have demonstrated the advantages of using EVs for RNA delivery, there are still issues with EVs generated from fibroblasts and dendritic cells being not permanently available from all subjects [69,72].…”

Section: Advantages Of Red Blood Cell Extracellular Vesicles In Theramentioning

confidence: 99%

The Biology and Therapeutic Applications of Red Blood Cell Extracellular Vesicles

Zhang¹,

Kiomourtzis²,

Lam³

et al. 2019

Erythrocyte

View full text Add to dashboard Cite

This chapter focuses on the biology of red blood cell extracellular vesicles (RBCEVs) in normal and diseased conditions, and the potential application of RBCEVs in treatment. Extracellular vesicles (EVs) refer to membranous vesicles secreted by cells into the extracellular environment. EV biology belongs to a rapidly developing field in biomedical sciences. EVs represent a natural mode of cell-to-cell communication, which makes them suitable for delivery of therapeutic agents, such as nucleic acids and proteins, in the body. In particular, RBCEVs feature a wide range of benefits in drug delivery as compared to extracellular vesicles derived from other cell types. In comparison to other delivery systems currently available, RBCEVs are nontoxic, low immunogenic, conveniently obtainable, and easy to use and store. Therefore, RBCEVs boast promising and exceptional advantages in overcoming various limitations of conventional therapeutics.

show abstract

Comparison of the size of membrane microparticles of different cellular origin by dynamic light scattering

Cited by 9 publications

References 7 publications

Platelet, erythrocyte, endothelial, and monocyte microparticles in coagulation activation and propagation

Platelet, erythrocyte, endothelial, and monocyte microparticles in coagulation activation and propagation

Microvesicles Released from Human Red Blood Cells: Properties and Potential Applications

The Biology and Therapeutic Applications of Red Blood Cell Extracellular Vesicles

Contact Info

Product

Resources

About